Pharmaceuticals

Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program

Practical, innovative functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience. PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic ar...

2022-12-07 08:00 1780

Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering

SYDNEY, Dec. 7, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today commenced its previously announced backstopped rights offering to raise gross proceeds of approximatelyUS$4.0 million (the "Rights Offering"). Under the terms of the Rights O...

2022-12-07 07:00 2928

Turn Biotechnologies Changes Paradigm in Skin Rejuvenation

* Data unveiled at four industry conferences suggest a single ERA treatment may be more effective than combination therapies used today * Biomarker analysis demonstrates ERA's regenerative impact on fibroblast proliferation, collagen VII production * eTurna™ lipid-based delivery platform p...

2022-12-06 22:00 2474

CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL

Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a globa...

2022-12-06 20:04 1328

Clarivate Expands Real World Data and Analytics Solutions with Addition of U.S. Specialty Pharmacy Data

LONDON, Dec. 6, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the inclusion of linked specialty pharmacy claims data within real world datasolutions. The new U.S. dataset will ex...

2022-12-06 18:20 1808

GenScript ProBio Congratulates Selecxine's IND Clearance from MFDS

SEOUL, South Korea, Dec. 6, 2022 /PRNewswire/ -- Recently, Selecxine, a partner of GenScript ProBio, announced MFDS clearance of its phase I/II clinical trial application for innovative antibody drug program (SLC-3010) . GenScript ProBio extended congratulations on this. SinceDecember 2019, GenSc...

2022-12-06 17:14 2557

Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis

HANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient in a Phase II clinical trial of its innovative drug LNK01003 in Ulcerative Colitis ...

2022-12-05 08:00 2327

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2022-12-05 08:00 2659

Telix Announces Executive Leadership Appointments

MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.  Richard Valei...

2022-12-05 06:39 1778

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS

The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis MIAMI, Dec. 3, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a$5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmen...

2022-12-03 01:07 3106

Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 - Lights up NY Times Square, NASDAQ

TAMPA, Fla., Dec. 2, 2022 /PRNewswire/ -- VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease.Concept Medical Inc . hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD...

2022-12-02 21:10 3313

Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies

JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "...

2022-12-02 18:23 3550

Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering

SYDNEY, Dec. 2, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the "Rights Offering") for qualifying shareholders of record as ofDecember 6, 20...

2022-12-02 10:05 3563

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.   ...

2022-12-01 21:00 3017

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday,30th November 2022,...

2022-12-01 03:45 1624

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant's PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

* Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors * Elacestrant side effects were manageable and consistent with previously reported result...

2022-12-01 00:56 1691

Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CAMBRIDGE, Mass., Nov. 30, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the first cohort has been dosed in a Phase 2 trial evaluating KP104 for the treatment of pa...

2022-11-30 20:00 1427

First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US

SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial inthe United States comparing HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently develo...

2022-11-30 08:00 2570

Probiotic strain SNZ 1969® helps manage IBS-D & IBS-C symptoms effectively, latest clinical study shows

HYDERABAD, India, Nov. 29, 2022 /PRNewswire/ -- Latest study shows Sanzyme Biologics'sBacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing ...

2022-11-29 15:44 2359

BGI Genomics, Naleya Genomics Indonesia, MGI, and Bumame contribute aid packages to Cianjur earthquake relief efforts

CIANJUR, Indonesia, Nov. 29, 2022 /PRNewswire/ -- A 5.6-magnitude earthquake struck the Cianjur district,West Java last Monday (Nov. 21, 2022). As part of earthquake relief efforts, BGI Genomics, its subsidiary Naleya Genomics Indonesia (NGI) and MGI are partnering withIndonesia's leading healthc...

2022-11-29 08:38 2602
1 ... 48495051525354 ... 180